Clinical Efficacy of Tobramycin Dexamethasone+Pranoprofen Eye Drops on Endophthalmitis in Cataract Patients Complicated with Diabetes Mellitus after Intraocular Lens Implantation.

Background: There is little research on the anti-inflammatory efficacy and safety of tobramycin dexamethasone+pranoprofen eye drops in treating endophthalmitis.

Aim: To appraise the efficacy and safety of tobramycin dexamethasone+propranolofen eye drops in the treatment of endophthalmitis.

Methods: The degree of corneal edema, foveal thickness, score of anterior chamber (AC) flares, best corrected visual acuity (BCVA), fasting blood glucose, inflammatory indexes of serum and aqueous humor, and adverse reactions were observed every week.

Results: After the intervention with tobramycin dexamethasone+pranoprofen eye drops, corneal edema and foveal thickness reduced, BCVA improved, and the inflammatory markers in serum and aqueous humor decreased. Moreover, the incidence of adverse reactions in the tobramycin dexamethasone+pranoprofen group was lower than that in the control group and the fluorometholone group (P < 0.05).

Conclusion: Tobramycin dexamethasone+pranoprofen eye drops can inhibit inflammation better, recover vision faster, and make the incidence of adverse reactions lower in treating cataract patients complicated with DM developing endophthalmitis induced.